Detecting Alzheimer’s Disease Early through a Blood Test
John McDonough, executive chair and CEO of Sunbird Bio, discusses the company’s diagnostic test in development for Alzheimer’s disease, how it has the potential to impact treatments and outcomes for millions of patients with the condition, and how its merger with Glympse Bio is expected to push it into new markets.